Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026)

Exelixis' (EXEL) quarterly Total Non-Current Liabilities came in at $540.5 million in Q2 2026, down 7.8% year-on-year from $586.2 million in Q2 2025, and down 6.6% quarter-over-quarter from $578.7 million in Q1 2026.

Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Exelixis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $540.5 million for Q2 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 7.8% year-over-year to $540.5 million in Q2 2026; TTM through Apr 2026 was $540.5 million, a 7.8% decrease from a year earlier, with the FY2026 full-year figure at $578.7 million, down 2.68% from the prior year.
  • Total Non-Current Liabilities eased to $540.5 million in Q2 2026 per EXEL's latest filing, from $578.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $594.6 million in Q1 2025 and bottomed at $347.8 million in Q2 2022.
  • The 5-year median for Total Non-Current Liabilities is $543.7 million (2024), against an average of $534.7 million.
  • Across the five-year window, Total Non-Current Liabilities soared 49.78% in 2023 and decreased 7.8% in 2026, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $514.5 million in 2022, then rose by 13.54% to $584.2 million in 2023, then rose by 0.78% to $588.8 million in 2024, then retreated by 6.55% to $550.2 million in 2025, then retreated by 1.77% to $540.5 million in 2026.
  • Per Business Quant, the three latest EXEL Total Non-Current Liabilities figures stand at $540.5 million (Q2 2026), $578.7 million (Q1 2026), and $550.2 million (Q4 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Exelixis 14.38 Bn 13.60 Bn 590.86 Mn 540.52 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 540.52 Mn
Jan 2, 2026 578.68 Mn
Oct 3, 2025 550.24 Mn
Jul 4, 2025 515.95 Mn
Apr 4, 2025 586.23 Mn
Jan 3, 2025 594.59 Mn
Sep 27, 2024 588.79 Mn
Jun 28, 2024 543.72 Mn
Mar 29, 2024 574.48 Mn
Dec 29, 2023 584.22 Mn
Sep 29, 2023 567.67 Mn
Jun 30, 2023 541.04 Mn
Mar 31, 2023 520.84 Mn
Dec 30, 2022 514.53 Mn
Sep 30, 2022 468.06 Mn
Jul 1, 2022 472.75 Mn
Apr 1, 2022 347.75 Mn
Dec 31, 2021 397.60 Mn
Oct 1, 2021 331.20 Mn
Jul 2, 2021 317.13 Mn